Literature DB >> 12189437

Quantitation of basal endogenous glucose production in Type II diabetes: importance of the volume of distribution.

J Radziuk1, S Pye.   

Abstract

The rate of endogenous glucose production (EGP) is important in understanding the pathophysiology of Type II (non-insulin-dependent) diabetes mellitus, the aetiology of its complications, and the identification of potential therapeutic targets. A great deal of effort has therefore been expended in its evaluation. Most measurements in humans have been made using tracers, or labelled analogues of glucose. Experimental strategies have included the injection and the infusion of such tracers which were often primed to achieve constant concentrations of the label more quickly. Primers have either been fixed or adjusted to the ambient glycaemia in each diabetic subject. Analyses were carried out using steady-state or non-steady-state calculations, the latter based on a one-compartment model or higher order systems. The principal finding of this review is that all approaches yield the same EGP when an appropriate model of the system is used. Under basal conditions, a single compartment model is sufficient to evaluate EGP, but the estimation of the volume of distribution, V, from individual data is critical in obtaining consistent results. Other sources of variation arose from the length of the fasting period and the patient population being studied. Overall, in Type II diabetes, EGP is frequently high in the morning and decreases gradually to rates comparable to healthy control subjects. This can be a very delayed response to a preceding meal, but more likely corresponds to an accentuated circadian rhythm in glucose production. Metabolic clearance of glucose, on the other hand, is decreased in diabetes, and remains so during the course of the day.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12189437     DOI: 10.1007/s00125-002-0841-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

Review 1.  The role of the liver in type 2 diabetes.

Authors:  Peter Staehr; Ole Hother-Nielsen; Henning Beck-Nielsen
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

2.  Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour?

Authors:  J Radziuk; S Pye
Journal:  Diabetologia       Date:  2006-05-16       Impact factor: 10.122

3.  Neuroendocrine inhibition of glucose production and resistance to cancer in dwarf mice.

Authors:  J McKee Alderman; Kevin Flurkey; Natasha L Brooks; Sneha B Naik; Jonathan M Gutierrez; Urmila Srinivas; Kristen B Ziara; Linhong Jing; Gunnar Boysen; Rod Bronson; Simon Klebanov; Xian Chen; James A Swenberg; Mats Stridsberg; Carol E Parker; David E Harrison; Terry P Combs
Journal:  Exp Gerontol       Date:  2008-06-07       Impact factor: 4.032

4.  Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process.

Authors:  Dongyang Liu; Yi Zhang; Ji Jiang; John Choi; Xuening Li; Dalong Zhu; Dawei Xiao; Yanhua Ding; Hongwei Fan; Li Chen; Pei Hu
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

5.  SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase.

Authors:  Gaëlle Laurent; Natalie J German; Asish K Saha; Vincent C J de Boer; Michael Davies; Timothy R Koves; Noah Dephoure; Frank Fischer; Gina Boanca; Bhavapriya Vaitheesvaran; Scott B Lovitch; Arlene H Sharpe; Irwin J Kurland; Clemens Steegborn; Steven P Gygi; Deborah M Muoio; Neil B Ruderman; Marcia C Haigis
Journal:  Mol Cell       Date:  2013-06-06       Impact factor: 17.970

Review 6.  [Future targets in the treatment of type 2 diabetes].

Authors:  Harald Stingl; Michael Roden
Journal:  Wien Klin Wochenschr       Date:  2004-04-30       Impact factor: 1.704

7.  Direct and indirect effects of amino acids on hepatic glucose metabolism in humans.

Authors:  M Krebs; A Brehm; M Krssak; C Anderwald; E Bernroider; P Nowotny; E Roth; V Chandramouli; B R Landau; W Waldhäusl; M Roden
Journal:  Diabetologia       Date:  2003-06-18       Impact factor: 10.122

8.  Blood glucose increments as a measure of body physiology.

Authors:  Robert G Hahn
Journal:  Crit Care       Date:  2005-02-28       Impact factor: 9.097

9.  Characteristics of glucose metabolism in Nordic and South Asian subjects with type 2 diabetes.

Authors:  Cecilie Wium; Hanne Løvdal Gulseth; Erik Fink Eriksen; Kåre Inge Birkeland
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

10.  The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.

Authors:  Sofie Hædersdal; Asger Lund; Elisabeth Nielsen-Hannerup; Henrik Maagensen; Gerrit van Hall; Jens J Holst; Filip K Knop; Tina Vilsbøll
Journal:  Diabetes       Date:  2020-10-01       Impact factor: 9.337

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.